Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Presentation

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

FDA Updates of COVID-19 Vaccine Safety Activities

Vaccines and Related Biological Products Advisory Committee
June 10, 2021

Steve Anderson, PhD, MPP
Director, Office of Biostatistics and Epidemiology (OBE)
FDA - Center for Biologics Evaluation and Research (CBER)

US Vaccine Surveillance Programs: Post-Authorization

Passive Surveillance of Vaccines

a. Vaccine Adverse Event Reporting System (VAERS)
   - Management shared by CDC and FDA
   - Discussed by Dr. Shimabukuro - CDC

FDA Vaccine Active Surveillance Programs: Post-Authorization

Active Surveillance Monitoring Programs

a. **FDA-CMS Medicare data**: Claims data
b. **FDA BEST system**: Claims and EHR data

FDA-CMS Medicare Data: Active Surveillance

Federal Partners

- Data cover very large population of approximately 34 million elderly US beneficiaries ≥ 65 years of age
- >92% of US elderly use Medicare
- Consists of claims data with access to medical charts

FDA BEST: Active Surveillance

Biologics Effectiveness and Safety Initiative

- Use of claims data for Vaccine Safety:
  - 3 major partners – Optum, CVS Health, HealthCore
- Emphasis on detection of rare vaccine adverse events (<1/100,000 doses)

FDA Near Real-Time Surveillance COVID-19 Vaccines:

CMS + BEST Claims Databases

Data Source (Claims)	Update Frequency	Number of Patients Covered, Millions (National)	Status of Rapid Cycle Analyses
CMS	Daily	**105**	Initiated early March
Optum* (Pre-Adjudicated)	Bi-Weekly	**22**	Initiated mid-May
CVS Health*	Monthly	**26**	Initiation: 1st week of June
HealthCore*	Monthly	**76**	Initiation: 3rd week of June

**Major Sentinel PRISM Partners*

FDA Near Real-Time Surveillance
COVID-19 Vaccine Dose Totals
CMS + BEST Claims Databases

Databases	Pfizer	Moderna	Janssen
CMS* **(data cutoff: 05/22/2021)**	8,630,677	8,815,039	309,315
Optum (Pre-adjudicated) **(data cutoff: 05/17/2021)**	1,971,547	1,178,754	129,369
CVS Health **(data cutoff: 04/30/2021)**	1,648,417	1,122,970	104,267
HealthCore **(data cutoff: 05/31/2021)**	3,508,200	2,507,711	214,111

*65+ years

FDA COVID-19 Vaccine Safety Signal Detection

Conducting “Near real-time surveillance” of 16 safety outcomes of interest :

- Approach used by US government agencies for H1N1 Monitoring in 2009 & 2010

- Approach routinely used by FDA and CDC annually for vaccines

FDA Near Real-Time Surveillance of COVID-19 Vaccines

Working list of at least 16 possible adverse events of special interest (AESI)

Acute myocardial infarction	Bell's Palsy	Narcolepsy
Anaphylaxis	Encephalomyelitis	Non-hemorrhagic Stroke
Appendicitis	Guillain-Barré syndrome	Pulmonary Embolism (PE)
Disseminated intravascular coagulation (DIC)	Hemorrhagic Stroke	Transverse Myelitis
Deep Vein Thrombosis (DVT)	Myocarditis/Pericarditis	Immune thrombocytopenia (ITP)
	Thrombosis with Thrombocytopenia	

Data Coverage of US population

- US government-wide approach provides advantages in covering broader portion of US population
- Primary coverage by three age stratifications
  - ≥ 65 years: FDA-CMS (VSD, VA, BEST)
  - 18 - 64 years: VSD, VA, BEST
  - ≤17 years: VSD, BEST

FDA BEST Data Coverage of US population:

Pediatric Population: Number of Enrollees from January 2021-Present

Data Source	Age < 12 years	Age 12-17 years	Age 18-64 years
CVS Health	2,209,147	1,320,594	12,562,033
Optum (Pre-adjudicated)	1,943,993	1,149,942	10,613,669
HealthCore	2,688,839	1,694,841	15,630,314

Initial Results Myocarditis/Pericarditis Near Real-Time Surveillance in BEST and CMS

Database	Vaccine	Vaccine Doses	Myocarditis/Pericarditis Events after Vaccination (42 days risk interval)	Safety Signal
Optum Pre-adjudicated, ages 12-64 years (data through 5/17)	Pfizer-BioNTech	1.9 M	63	No
	Moderna	1.1 M	32	No
	Janssen	0.13 M	4	No
CMS, ages ≥65 years (data through 5/22)	Pfizer-BioNTech	8.6 M	636	No
	Moderna	8.8 M	601	No
	Janssen	0.31 M	23	No

Next Steps

Epidemiological Studies to follow up on potential signals identified by VAERS and Near Real-Time Surveillance:

- Study Protocols – inferential studies, SCRI, cohort analyses, etc.
  - To follow CVST/TTS and Myocarditis/Pericarditis
  - Focus on subpopulations – pediatric, pregnant persons, elderly and residents of long-term care facilities, comorbidities, etc.

Acknowledgments

- Richard Forshee
- Azadeh Shoaibi
- Hui-Lee Wong
- CBER Surveillance Team
- Manette Niu
- CBER OBE Colleagues
- CDC Colleagues
- CMS Colleagues
- VA Colleagues
- FDA Partners: Acumen, IBM Watson – and new partners in FY2021

Thank you!

Questions?

RESERVE SLIDES

FDA BEST COVID-19 Vaccine Protocols

1. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol
2. COVID-19 Vaccine Safety Surveillance: Active Monitoring Master Protocol
3. Assessment of Risk of Safety Outcomes Following COVID-19 Vaccination Draft Master Protocol
4. Assessment of the Performance of COVID-19 Diagnosis Code Using SARS-CoV-2 Test Results Draft Protocol

www.bestinitiative.org

CBER Surveillance Program Collaborative

Through multiple contracts and partnerships, CBER works with a diverse group of scientists and clinicians to conductactivesurveillance.

*CERSI: Centers of Excellence in Regulatory Science and Innovation